Search Results
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
0.1×106 CAR T cells/kg. Cytokine release syndrome occurred in 12 patients (60%), all graded as 1 or 2. No Grade ≥3 cytokine release syndrome (CRS) occurred. One patient (5%) experienced Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS). No treatment-related deaths occurred.
More news about: CARsgen Therapeutics
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older. INDICATION AVTOZMA® (tocilizumab-anoh)
More news about: Celltrion
Oct 01, 2025, 14:00 ET Beyond Expectations: Kubota Unveils Next-Generation Grand L70 Series Compact Tractors
hp, empowering operators to tackle a wide variety of jobs with power, confidence and efficiency. The Grand L70 utilizes Kubota's Common-Rail System (CRS) with electronically controlled fuel injection for smooth, efficient operation. Both models are available in 3- or 4-cylinder configurations; the deluxe
More news about: Kubota Tractor Corporation
Oct 01, 2025, 07:30 ET IBS Software Unveils AI-Powered Virtual Agents to Transform Air Cargo at 25th Cargo Forum
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Oct 01, 2025, 07:00 ET Public Launches Fully Customizable Direct Indexing
Form CRS, and
More news about: Public
Sep 23, 2025, 08:00 ET Dominari Holdings Announces Board Member Tim Ledwick to Assume Role of Interim Chief Financial Officer
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Sep 22, 2025, 11:02 ET CellPoint Digital lanza One Source Orchestration, la primera plataforma de optimización de pagos para satisfacer la demanda de los modelos de venta minorista OOSD
que manejan la industria de viajes, incluidos los sistemas de distribución global (GDS, por sus siglas en inglés), los sistemas centrales de reservas (CRS), los sistemas de gestión de propiedades (PMS), los sistemas de gestión de ofertas y los conectores previamente construidos para los sistemas de servicio
More news about: CellPoint Digital
Sep 22, 2025, 01:00 ET CellPoint Digital Launches One Source Orchestration, the First Payment Optimization Platform to Meet the Demand of OOSD Retailing Models
friction. OSO also integrates with the core systems that run the travel industry, including Global Distribution Systems (GDS), Central Reservation Systems (CRS), Property Management Systems (PMS), Offer Management Systems, and features pre-built connectors to airline Passenger Service Systems (PSS). It can be
More news about: CellPoint Digital
Sep 22, 2025, 01:00 ET CellPoint Digital Launches One Source Orchestration, the First Payment Optimization Platform to Meet the Demand of OOSD Retailing Models
friction. OSO also integrates with the core systems that run the travel industry, including Global Distribution Systems (GDS), Central Reservation Systems (CRS), Property Management Systems (PMS), Offer Management Systems, and features pre-built connectors to airline Passenger Service Systems (PSS). It can be
More news about: CellPoint Digital
Sep 19, 2025, 08:30 ET TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Sep 19, 2025, 08:00 ET Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Sep 19, 2025, 08:00 ET Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Sep 18, 2025, 21:39 ET 2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
achieved CR or sCR, the median duration of MRD negativity was 36.5 months. Manageable long-term safety profile CRS occurred in 93.6% of patients, with only one case≥grade 3;ICANS was reported in two patients (grade 1–2);No late-onset neurotoxicity
More news about: IASO Bio
Sep 17, 2025, 20:15 ET CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
median follow-up duration was 53.3 months (range:14.8, 63.5). Regarding safety: There were no reports of ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy or other delayed AEs on the study.
More news about: CARsgen Therapeutics
Sep 17, 2025, 17:09 ET MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
much as 20 points in all 5 patients 3 months after the infusion of HN2301. The treatment was generally well tolerated, no patients experienced grade ≥3 CRS, and no neurotoxic effects or other severe adverse events were observed during or after treatment. Based on these encouraging clinical results,
More news about: Shenzhen MagicRNA Biotech Co., Ltd.
Sep 17, 2025, 05:00 ET IBS Software and Emirates Skywards Launch Strategic Partnership and Successfully Deploy Next-Gen iLoyal Loyalty Platform
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Sep 15, 2025, 07:01 ET Amadeus and Shiji partner to offer hotels a complete hospitality technology suite
providing new single-image integrations, we are offering an unparalleled solution that addresses historical fragmentation and delivers the best in PMS, POS, CRS, sales and catering, and hotel operations technology." About Amadeus Amadeus makes the experience of travel better for everyone,
More news about: Shiji Group
Sep 12, 2025, 12:37 ET ISS National Lab Advances Research in Space With Dozens of Experiments on Next Cargo Mission
Northrop Grumman CRS-23 About the International Space Station (ISS) National Laboratory:The International Space Station (ISS) is a one-of-a-kind
More news about: International Space Station National Lab
Sep 12, 2025, 01:51 ET IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
T2 hyperintense lesions in any of the patients.Safety Four of five patients experienced transient grade 1 CRS;No ICANS or other neurologic toxic effects were observed post infusion;Only grade ≥3 neutropenia and lymphocyte count decreased were
More news about: IASO Bio
Sep 10, 2025, 08:30 ET Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Sep 09, 2025, 08:00 ET Dominari Holdings Applauds American Bitcoin's Nasdaq Debut; Highlights Strategic Stake
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Sep 05, 2025, 12:14 ET Media Webinar Showcases Research Launching on Upcoming Mission to the ISS
Northrop Grumman CRS-23 KENNEDY SPACE CENTER, Fla., Sept. 5, 2025 /PRNewswire/ -- The next Northrop Grumman commercial resupply services (CRS) mission to the
More news about: International Space Station National Lab
Sep 05, 2025, 09:21 ET Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC
rate (ORR) was 50% (6/12) in MCL patients, including 1 complete response (CR) and 5 partial responses (PR). The ORR was 100% (2/2) in cHL patients with CRs. The preliminary results of this Phase I clinical trial show that HDM2005 was well-tolerated and demonstrated promising anti-tumor activity in
More news about: HUADONG MEDICINE
Sep 05, 2025, 08:30 ET Advanced Therapy Safety Management: Proactive Strategies for Real-World Risk Detection, Upcoming Webinar Hosted by Xtalks
complex safety challenges due to their immune-mediated mechanisms of action and novel manufacturing processes. These include cytokine release syndrome (CRS), neurotoxicity and/or other severe inflammatory responses as well as delayed-onset toxicities including secondary malignancies. As such, proactive safety
More news about: Xtalks
Sep 03, 2025, 09:00 ET Modera Wealth Management Expands Tax Practice Through Transaction with Ferrentino & Associates
www.adviserinfo.sec.gov) to obtain a copy of our disclosure statement, Form ADV Part 2A, and ADV Part 3/Form CRS. In addition, our Privacy Notice outlines how we handle your non-public personal information. Please read these documents carefully before you make a
More news about: Modera Wealth Management, LLC